Revolution Medicines (RVMD) Share-based Compensation (2019 - 2026)

Revolution Medicines has reported Share-based Compensation for 8 years, with the latest figure at $87.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 248.03% year-over-year to $87.3 million; the trailing twelve-month figure through Mar 2026 stood at $180.6 million (up 105.06% YoY), and the FY2025 full-year result was $118.4 million, up 49.49% from the prior year.
• Share-based Compensation for Q1 2026 stood at $87.3 million, up from $33.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $87.3 million in Q1 2026, with the low at $6.6 million in Q1 2022.
• Average Share-based Compensation over 5 years is $22.2 million, with a median of $19.8 million recorded in 2024.
• Year-over-year, Share-based Compensation slipped 11.75% in 2024 and soared 248.03% in 2026.
• Tracing RVMD's Share-based Compensation over 5 years: stood at $8.3 million in 2022, then soared by 205.76% to $25.4 million in 2023, then dropped by 11.75% to $22.4 million in 2024, then jumped by 50.17% to $33.7 million in 2025, then soared by 159.08% to $87.3 million in 2026.
• The last three Share-based Compensation figures came in at $87.3 million (Q1 2026), $33.7 million (Q4 2025), and $30.8 million (Q3 2025), per Business Quant data.

Peer Comparison